Mirabegron Avansor: Uses, Dosage & Side Effects
A selective beta-3 adrenoceptor agonist for the symptomatic treatment of overactive bladder with urgency, increased urinary frequency, and urge incontinence in adults
Mirabegron Avansor is a prescription medication containing mirabegron, a selective beta-3 adrenoceptor agonist used for the symptomatic treatment of overactive bladder (OAB) in adults. Unlike traditional antimuscarinic therapies, mirabegron works by activating beta-3 adrenergic receptors on the detrusor smooth muscle, promoting bladder relaxation during the filling phase and increasing functional bladder capacity. The prolonged-release 50 mg tablet is taken once daily and has been shown in large randomized controlled trials to significantly reduce urgency episodes, urinary frequency, and urge incontinence episodes, with a favorable tolerability profile that avoids the anticholinergic side effects commonly associated with older OAB medications such as dry mouth and constipation.
Quick Facts: Mirabegron Avansor
Key Takeaways
- Mirabegron Avansor is a beta-3 adrenoceptor agonist that relaxes the bladder muscle during the filling phase, providing an effective treatment for overactive bladder symptoms including urgency, frequency, and urge incontinence in adults.
- Unlike antimuscarinic medications, mirabegron generally does not cause dry mouth, constipation, or cognitive side effects, making it a preferred option for patients who cannot tolerate or have contraindications to anticholinergic drugs.
- The recommended dose is one 50 mg prolonged-release tablet taken once daily with or without food; the tablet should be swallowed whole with water and not crushed, divided, or chewed.
- Blood pressure should be monitored before starting and periodically during treatment, as mirabegron can cause small increases in blood pressure; it is contraindicated in patients with severe uncontrolled hypertension.
- Clinical trials (SCORPIO, ARIES, DRAGON) demonstrated significant reductions in incontinence episodes and urinary frequency, with therapeutic benefits typically becoming apparent within 8 weeks of treatment initiation.
What Is Mirabegron Avansor and What Is It Used For?
Mirabegron Avansor belongs to a pharmacological class known as beta-3 adrenergic agonists. The active substance, mirabegron, was the first drug in this class to receive regulatory approval for the treatment of overactive bladder, representing a fundamentally new approach to managing this prevalent condition. While traditional OAB medications – the antimuscarinics such as oxybutynin, tolterodine, and solifenacin – work by blocking acetylcholine receptors to prevent involuntary detrusor contractions, mirabegron takes a different pharmacological approach by stimulating beta-3 adrenergic receptors on the bladder smooth muscle to promote active relaxation during the storage phase of the micturition cycle.
Overactive bladder is a highly prevalent condition affecting an estimated 12–17% of the adult population worldwide, with prevalence increasing with age. The condition is characterized by a symptom complex that includes urinary urgency (a sudden, compelling desire to pass urine that is difficult to defer), often accompanied by increased daytime urinary frequency (voiding 8 or more times during waking hours), nocturia (waking one or more times at night to urinate), and urge urinary incontinence (involuntary loss of urine associated with urgency). OAB significantly impacts quality of life, affecting sleep, social activities, work productivity, sexual function, and psychological well-being. Despite its prevalence, OAB remains underdiagnosed and undertreated, with many patients not seeking medical attention due to embarrassment or the misconception that urinary symptoms are a normal part of aging.
The beta-3 adrenoceptor is the predominant beta-adrenoceptor subtype expressed in the human urinary bladder detrusor smooth muscle. During the bladder filling (storage) phase, sympathetic nervous system activation releases noradrenaline, which activates these beta-3 receptors. This activation triggers a signaling cascade involving cyclic adenosine monophosphate (cAMP) that results in relaxation of the detrusor muscle, allowing the bladder to fill at low intravesical pressures and store urine without involuntary contractions. Mirabegron acts as a potent and selective agonist at these beta-3 adrenoceptors, mimicking and enhancing this physiological relaxation mechanism. By promoting detrusor relaxation during the storage phase, mirabegron increases the functional capacity of the bladder, reduces the frequency and intensity of urgency episodes, and decreases involuntary detrusor contractions that cause urge incontinence.
The clinical efficacy of mirabegron has been established in a comprehensive phase III clinical trial program that included three pivotal randomized, double-blind, placebo-controlled studies. The SCORPIO study, conducted primarily in Europe, enrolled 1,978 patients with OAB and demonstrated that mirabegron 50 mg once daily significantly reduced the mean number of incontinence episodes per 24 hours (primary endpoint) and the mean number of micturitions per 24 hours compared with placebo at 12 weeks. The ARIES study, conducted primarily in North America, enrolled 1,328 patients and confirmed these findings, showing statistically significant reductions in both incontinence episodes and micturition frequency. The DRAGON dose-ranging study in Asia further supported the efficacy profile. Across these studies, mirabegron 50 mg demonstrated reductions of approximately 1.5–1.7 incontinence episodes per 24 hours (compared with 1.1–1.2 for placebo) and reductions of approximately 1.7–1.8 micturitions per 24 hours (compared with 1.0–1.3 for placebo).
Long-term efficacy and safety data from 12-month extension studies have confirmed that the benefits of mirabegron treatment are sustained over time, with no evidence of tolerance development. Patients who continued mirabegron treatment maintained their improvements in urgency, frequency, incontinence, and quality of life measures. The SYNERGY and BESIDE studies further demonstrated that mirabegron can be used in combination with the antimuscarinic solifenacin for patients who require additional symptom control, providing a rational combination approach that targets two complementary pathways in bladder physiology.
Overactive bladder is a clinical syndrome defined by urgency, with or without urge incontinence, usually accompanied by frequency and nocturia, in the absence of urinary tract infection or other obvious pathology. It is not a disease of aging but a treatable medical condition. Behavioral therapies (bladder training, pelvic floor exercises) are recommended as first-line treatment, often combined with pharmacotherapy such as mirabegron for optimal symptom control.
What Should You Know Before Taking Mirabegron Avansor?
Before initiating treatment with Mirabegron Avansor, it is essential that both patients and healthcare providers carefully evaluate whether this medication is appropriate. While mirabegron has a generally favorable safety profile compared with antimuscarinic agents, there are specific situations in which its use is contraindicated or requires particular caution. Understanding these considerations helps ensure safe and effective treatment.
Contraindications
Mirabegron Avansor must not be used in the following circumstances:
- Hypersensitivity: Patients who are allergic to mirabegron or to any of the excipients listed in the product composition should not take this medication. Allergic reactions, although rare, can include skin rash, itching, urticaria, and in very rare cases, angioedema or anaphylaxis.
- Severe uncontrolled hypertension: Mirabegron is contraindicated in patients with a systolic blood pressure of 180 mmHg or higher and/or a diastolic blood pressure of 110 mmHg or higher. Since mirabegron can cause modest increases in blood pressure through its beta-adrenergic agonist activity, use in patients with severely elevated blood pressure could pose cardiovascular risks.
- Severe renal impairment: Patients with severe renal impairment (estimated glomerular filtration rate [eGFR] 15–29 mL/min/1.73 m²) or end-stage renal disease (eGFR <15 mL/min/1.73 m² or requiring hemodialysis) should not use this medication due to insufficient safety data and the potential for increased systemic exposure.
- Severe hepatic impairment: Patients with severe liver impairment (Child-Pugh Class C) should not take Mirabegron Avansor. The metabolism of mirabegron involves hepatic pathways, and severe liver dysfunction can lead to significantly increased drug exposure.
Warnings and Precautions
Several clinical situations require special attention when considering or continuing mirabegron therapy:
- Blood pressure monitoring: Mirabegron can cause dose-related increases in resting heart rate and blood pressure. In clinical trials, mean increases of approximately 1 mmHg in both systolic and diastolic blood pressure were observed with the 50 mg dose. Blood pressure should be measured at baseline and periodically during treatment. Patients with hypertension should have their blood pressure adequately controlled before starting mirabegron.
- Urinary tract infections: OAB symptoms can mimic or coexist with urinary tract infections. Urinary tract infection should be excluded before attributing symptoms to OAB and initiating mirabegron therapy.
- Bladder outlet obstruction: Mirabegron should be used with caution in patients with clinically significant bladder outlet obstruction (such as from benign prostatic hyperplasia) or in patients concurrently taking antimuscarinic medications for OAB. The theoretical concern is that promoting bladder relaxation in the setting of outlet obstruction could increase post-void residual volume and potentially precipitate urinary retention, although this has not been observed as a significant clinical problem in trials.
- Moderate renal or hepatic impairment: While not contraindicated, patients with moderate renal impairment (eGFR 30–59 mL/min/1.73 m²) or moderate hepatic impairment (Child-Pugh Class B) require careful monitoring. No dose adjustment is required for these patients at the 50 mg dose, but close clinical follow-up is advisable.
- Patients taking CYP2D6 substrates with narrow therapeutic index: Mirabegron is a moderate inhibitor of the CYP2D6 enzyme. When co-administered with medications that are metabolized by CYP2D6 and have a narrow therapeutic window (e.g., thioridazine, flecainide, propafenone), dose adjustment of the CYP2D6 substrate may be necessary (see Drug Interactions section).
Pregnancy and Breastfeeding
Mirabegron Avansor is not recommended during pregnancy. There are no adequate and well-controlled studies of mirabegron in pregnant women. Animal studies have shown reproductive toxicity at doses substantially higher than the human therapeutic dose, including decreased fetal body weight and delayed ossification. Women of childbearing potential should use effective contraception during treatment. If pregnancy occurs or is planned, the patient should discuss the risks and benefits with her healthcare provider.
It is not known whether mirabegron is excreted in human breast milk. In animal studies, mirabegron was detected in the milk of lactating rats. A decision must be made whether to discontinue breastfeeding or to discontinue mirabegron therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
Do not start Mirabegron Avansor if your blood pressure is severely elevated (systolic ≥180 mmHg or diastolic ≥110 mmHg). Have your blood pressure checked before starting treatment and at regular intervals during therapy. Report any symptoms such as severe headache, visual disturbances, or chest pain to your doctor immediately.
How Does Mirabegron Avansor Interact with Other Drugs?
Understanding drug interactions is crucial for the safe use of Mirabegron Avansor. Mirabegron undergoes metabolism via multiple pathways, including cytochrome P450 (CYP) enzymes 3A4 and 2D6, butyrylcholinesterase (BChE), uridine diphosphate-glucuronosyltransferases (UGTs), and direct amide hydrolysis. Additionally, mirabegron itself acts as a moderate inhibitor of CYP2D6 and a weak inhibitor of CYP3A4 at therapeutic concentrations. It also inhibits the drug efflux transporter P-glycoprotein (P-gp). These pharmacokinetic properties create the potential for clinically relevant interactions with certain co-administered medications.
Major Interactions
The following interactions are considered clinically significant and may require dose adjustment, enhanced monitoring, or avoidance of the combination:
| Drug | Mechanism | Effect | Recommendation |
|---|---|---|---|
| Digoxin | P-gp inhibition | Increased digoxin Cmax by 29% and AUC by 27% | Start digoxin at lowest dose; monitor serum digoxin levels |
| Thioridazine | CYP2D6 inhibition | Potentially significant increase in thioridazine exposure; QT prolongation risk | Avoid co-administration; use alternative antipsychotic |
| Flecainide | CYP2D6 inhibition | Increased flecainide plasma levels; risk of cardiac adverse effects | Dose adjustment of flecainide may be required; monitor ECG |
| Propafenone | CYP2D6 inhibition | Increased propafenone plasma levels; proarrhythmic risk | Dose adjustment of propafenone may be required; monitor ECG |
| Desipramine | CYP2D6 inhibition | Increased desipramine Cmax by 79% and AUC by 141% | Start desipramine at lowest dose; dose titrate carefully based on clinical response |
Moderate Interactions
The following interactions have been documented but are generally manageable with appropriate monitoring:
| Drug | Mechanism | Effect | Recommendation |
|---|---|---|---|
| Metoprolol | CYP2D6 inhibition | Increased metoprolol Cmax by 90% and AUC by 229% | Dose adjustment of metoprolol may be needed; monitor heart rate and blood pressure |
| Warfarin | CYP2C9 (minor) | Warfarin Cmax increased by 4%, AUC unchanged; minimal clinical effect | No dose adjustment required; routine INR monitoring advised |
| Solifenacin | Pharmacodynamic and CYP3A4 | Minor increases in solifenacin exposure; additive bladder relaxation | Combination studied in clinical trials (BESIDE/SYNERGY); monitor for urinary retention |
| Ketoconazole / Itraconazole | Strong CYP3A4 inhibition | Increased mirabegron Cmax by 45% and AUC by 80% (ketoconazole data) | No dose adjustment at 50 mg; caution with potent CYP3A4 inhibitors |
Patients should always inform their healthcare provider about all medications they are currently taking, including prescription drugs, over-the-counter medications, herbal supplements, and vitamins. Of particular importance is the interaction with metoprolol, a widely used beta-blocker for hypertension and heart conditions. Co-administration with mirabegron resulted in a significant increase in metoprolol exposure (approximately 3.3-fold increase in AUC), which could potentially lead to exaggerated beta-blockade effects such as excessive heart rate reduction and hypotension. Patients taking metoprolol or other CYP2D6-metabolized beta-blockers concurrently with mirabegron should be monitored for signs and symptoms of excess beta-blockade.
It is noteworthy that mirabegron has no clinically significant interaction with oral contraceptives containing ethinylestradiol and levonorgestrel. In a dedicated interaction study, co-administration of mirabegron with combined oral contraceptives did not meaningfully alter the pharmacokinetics of either contraceptive component, confirming that mirabegron can be used safely in women taking hormonal contraceptives.
Patients who are known CYP2D6 poor metabolizers (approximately 6–10% of the Caucasian population) may have higher mirabegron plasma concentrations. While no specific dose adjustment is recommended, these patients should be monitored more closely for potential adverse effects, particularly when co-administered with other CYP2D6 substrates.
What Is the Correct Dosage of Mirabegron Avansor?
Mirabegron Avansor is formulated as a prolonged-release tablet designed for once-daily oral administration. The prolonged-release formulation uses a hydrophilic matrix system that controls the release of mirabegron over an extended period, providing consistent drug levels throughout the 24-hour dosing interval. This design minimizes peak-to-trough fluctuations in plasma concentration and supports once-daily dosing convenience, which is important for long-term treatment adherence in a chronic condition like overactive bladder.
Adults
Standard Adult Dosage
The recommended dose is 50 mg once daily, taken orally with or without food. The tablet should be swallowed whole with a glass of water. It is important not to crush, divide, or chew the tablet, as this would disrupt the prolonged-release mechanism and could lead to an immediate release of the entire dose, potentially causing higher peak plasma concentrations and increased risk of adverse effects.
Mirabegron can be taken at any time of day, but patients are generally advised to take it at the same time each day to help maintain consistent drug levels and support treatment adherence. There is no specific requirement to take it with or after meals, as food does not significantly affect the overall bioavailability of mirabegron, although it may slightly reduce the rate of absorption.
Elderly Patients
Elderly (≥65 years)
No dose adjustment is required for elderly patients. Pharmacokinetic studies have shown that age does not have a clinically meaningful effect on mirabegron exposure. In the pivotal clinical trials, approximately 45% of enrolled patients were aged 65 years or older, and no differences in efficacy or safety were observed between older and younger adults. Mirabegron is therefore considered appropriate for use in the elderly population, which represents a significant proportion of OAB patients.
Renal and Hepatic Impairment
Renal Impairment
Mild impairment (eGFR 60–89 mL/min/1.73 m²): No dose adjustment required.
Moderate impairment (eGFR 30–59 mL/min/1.73 m²): No dose adjustment required. Monitor blood pressure.
Severe impairment (eGFR 15–29 mL/min/1.73 m²) or end-stage renal disease: Contraindicated due to insufficient safety data.
Hepatic Impairment
Mild impairment (Child-Pugh Class A): No dose adjustment required.
Moderate impairment (Child-Pugh Class B): No dose adjustment required. Close monitoring advised.
Severe impairment (Child-Pugh Class C): Contraindicated.
Children and Adolescents
Pediatric Population (<18 years)
The safety and efficacy of mirabegron in children and adolescents below 18 years of age have not been established. Mirabegron Avansor is therefore not recommended for use in the pediatric population. Alternative treatments should be considered under the guidance of a pediatric urologist or continence specialist.
Missed Dose
If a dose is missed, the patient should take the missed dose as soon as they remember, provided it is not close to the time of the next scheduled dose. If it is nearly time for the next dose, the patient should skip the missed dose and resume the regular dosing schedule. The patient should not take a double dose to make up for a forgotten dose. Given the long half-life of mirabegron (approximately 50 hours), missing a single dose is unlikely to result in a significant loss of therapeutic effect, as some drug will still be present from previous doses.
Overdose
Mirabegron has been administered in single doses up to 400 mg in healthy volunteers. At these supratherapeutic doses, adverse effects included increased heart rate and elevated blood pressure (increases of up to 14.2 bpm in pulse rate, and up to 24.7/15.8 mmHg in systolic/diastolic blood pressure were observed at 400 mg). There is no specific antidote for mirabegron overdose. In the event of a suspected overdose, symptomatic and supportive treatment is recommended. Cardiovascular monitoring, including heart rate and blood pressure measurement, is advised. Because mirabegron is highly protein-bound (approximately 71%), hemodialysis is unlikely to be effective in enhancing drug removal.
Take Mirabegron Avansor at the same time each day for consistent efficacy. Set a daily reminder if needed. The tablet can be taken with or without food. Always swallow the tablet whole – do not crush, chew, or break it. If you have difficulty swallowing tablets, discuss alternative treatment options with your healthcare provider.
What Are the Side Effects of Mirabegron Avansor?
Like all medicines, Mirabegron Avansor can cause side effects, although not everybody gets them. The safety of mirabegron 50 mg has been evaluated in a comprehensive clinical development program involving over 10,000 patients with overactive bladder. The overall incidence of adverse events with mirabegron was comparable to placebo in controlled clinical trials, and the discontinuation rate due to adverse events was low (approximately 3–4%). The side effect profile of mirabegron is notably different from that of antimuscarinic agents, with significantly lower rates of dry mouth (the most common reason for discontinuation of antimuscarinics) and constipation.
Side effects are categorized below by frequency, based on data from clinical trials and post-marketing surveillance:
Common
May affect up to 1 in 10 people
- Urinary tract infection (UTI)
- Tachycardia (increased heart rate)
- Nasopharyngitis (common cold symptoms)
- Headache
- Constipation
- Nausea
- Diarrhea
Uncommon
May affect up to 1 in 100 people
- Bladder infection (cystitis)
- Elevated blood pressure (hypertension)
- Dyspepsia (indigestion)
- Gastritis (stomach inflammation)
- Dizziness
- Vaginal infection
- Joint swelling
- Vulvovaginal pruritus (itching)
- Elevated liver enzymes (ALT/GGT)
- Urticaria (hives), rash, skin eruptions
Rare
May affect up to 1 in 1,000 people
- Eyelid edema (swelling around the eyes)
- Lip edema (swelling of the lips)
- Urinary retention
- Palpitations
- Small vessel cutaneous vasculitis (inflammation of small blood vessels in the skin)
- Purpura (purple discoloration of the skin)
- Leukocytoclastic vasculitis
Not Known
Frequency cannot be estimated from available data
- Angioedema (severe allergic swelling of face, lips, tongue, or throat)
- Hypertensive crisis
- Atrial fibrillation
- Insomnia
The cardiovascular effects of mirabegron deserve particular attention. As a beta-3 adrenergic agonist, mirabegron has the potential to cause small increases in heart rate and blood pressure. In clinical trials, mean increases of approximately 1 beat per minute in resting heart rate and approximately 1 mmHg in systolic and diastolic blood pressure were observed. While these mean changes are small and generally not clinically significant at the population level, individual patients may experience more pronounced effects. Tachycardia was reported in approximately 1–2% of patients receiving mirabegron 50 mg, compared with less than 1% of patients receiving placebo. Patients with pre-existing cardiovascular conditions should be monitored accordingly.
Post-marketing surveillance has identified additional rare adverse events that were not captured in the original clinical trial data. These include reports of hypertensive crisis (extremely high blood pressure requiring urgent medical treatment), atrial fibrillation, and angioedema. While these events are very rare, patients should be informed about warning signs that warrant immediate medical attention, including severe headache, chest pain, rapid or irregular heartbeat, and facial or throat swelling.
Notably, the incidence of dry mouth with mirabegron (approximately 2%) is substantially lower than with antimuscarinic agents (which can range from 10% to over 30% depending on the specific drug and dose). This is a significant clinical advantage, as dry mouth is the most common reason patients discontinue antimuscarinic therapy. Similarly, constipation rates with mirabegron are lower than with most antimuscarinics, and there is no evidence of adverse effects on cognitive function, an important consideration for elderly patients who may be vulnerable to anticholinergic cognitive burden.
Seek medical help immediately if you experience: severe allergic reactions (difficulty breathing, swelling of face, lips, tongue, or throat), very fast or irregular heartbeat, severe headache with visual disturbances (possible hypertensive crisis), or inability to urinate (urinary retention). Stop taking Mirabegron Avansor and contact your doctor or go to the nearest emergency department.
How Should You Store Mirabegron Avansor?
Proper storage of Mirabegron Avansor is important to maintain the quality, stability, and efficacy of the medication throughout its shelf life. The prolonged-release formulation relies on a specific matrix system to control drug release over time, and exposure to excessive heat or moisture could potentially compromise this mechanism.
The following storage guidelines should be observed:
- Temperature: Store below 30°C (86°F). Do not freeze. Avoid storing the medication in areas subject to extreme temperature fluctuations, such as near windows, radiators, or in the bathroom.
- Moisture protection: Keep the tablets in the original blister packaging until the time of use. The blister packaging is designed to protect the tablets from moisture, which is important for maintaining the integrity of the prolonged-release formulation.
- Light protection: While no specific light protection requirements are indicated, storing the medication in the original carton provides additional protection from light.
- Child safety: Keep this medicine out of the sight and reach of children. Use child-resistant storage if available.
- Expiry date: Do not use Mirabegron Avansor after the expiry date stated on the carton and blister (EXP). The expiry date refers to the last day of that month.
- Disposal: Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help to protect the environment and prevent accidental exposure.
If you notice any change in the appearance of the tablets (discoloration, unusual odor, visible damage to the tablet surface), do not use them and consult your pharmacist. Always check the packaging and tablets before each dose to ensure they appear normal and the blister packaging is intact.
What Does Mirabegron Avansor Contain?
Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific pharmaceutical excipients. Below is a detailed breakdown of the active and inactive ingredients in Mirabegron Avansor 50 mg prolonged-release tablets:
Active Substance
Each prolonged-release tablet contains 50 mg of mirabegron. Mirabegron is a synthetic compound with the chemical name 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide. It has a molecular weight of 396.51 Da and appears as a white to pale yellow crystalline powder. Mirabegron is practically insoluble in water at physiological pH, which is one of the reasons it is formulated as a prolonged-release tablet with a matrix system designed to control dissolution and absorption.
Excipients
The inactive ingredients serve specific functions in the tablet formulation:
- Polyethylene oxide (PEO): Forms the hydrophilic matrix that controls the rate of drug release from the tablet. When the tablet contacts gastrointestinal fluid, the PEO swells to form a gel layer that gradually erodes and releases mirabegron over an extended period.
- Polyethylene glycol (PEG): Acts as a plasticizer in the film coating and contributes to the tablet matrix.
- Hydroxypropyl cellulose (HPC): Functions as a binder and matrix-forming agent, contributing to the prolonged-release characteristics.
- Butylated hydroxytoluene (BHT, E321): An antioxidant that protects the active ingredient from oxidative degradation during storage.
- Magnesium stearate: A lubricant that facilitates tablet manufacturing by preventing the powder from sticking to production equipment.
Film coating: The tablet is coated with a film that contains hypromellose (HPMC), yellow iron oxide (E172), red iron oxide (E172), and titanium dioxide (E171). The coating gives the tablet its characteristic appearance and provides additional protection for the formulation. The 50 mg tablets are typically oval-shaped, yellow-brown in color, and debossed with identifying markings on one side.
Patients with known intolerance to any of these excipients should inform their healthcare provider before starting treatment. Notably, this formulation does not contain lactose, gluten, or sucrose, which may be relevant for patients with specific dietary restrictions or intolerances.
Frequently Asked Questions
Mirabegron and antimuscarinics (such as oxybutynin, tolterodine, and solifenacin) treat overactive bladder through completely different pharmacological mechanisms. Antimuscarinics block muscarinic acetylcholine receptors on the bladder muscle to prevent involuntary contractions, while mirabegron activates beta-3 adrenergic receptors to promote active relaxation of the bladder muscle during the filling phase. This fundamental difference in mechanism translates to a different side effect profile: mirabegron generally causes much less dry mouth, constipation, and cognitive impairment than antimuscarinic agents. This makes mirabegron a particularly attractive option for elderly patients who may be vulnerable to anticholinergic cognitive burden, and for patients who have discontinued antimuscarinics due to side effects.
Yes, mirabegron can cause modest increases in blood pressure. In clinical trials, the mean increase was approximately 1 mmHg for both systolic and diastolic blood pressure at the 50 mg dose, which is generally not clinically significant. However, individual patients may experience larger increases. Your doctor should measure your blood pressure before you start taking Mirabegron Avansor and should monitor it periodically during treatment. The medication is contraindicated in patients with severe uncontrolled hypertension (systolic ≥180 mmHg or diastolic ≥110 mmHg). If you have existing hypertension, it should be adequately controlled before starting mirabegron.
While some patients may begin to notice improvement in OAB symptoms within the first few weeks, the full therapeutic effect of mirabegron typically develops over 8 to 12 weeks of consistent daily use. In the pivotal clinical trials (SCORPIO, ARIES, and DRAGON), the primary efficacy endpoints were evaluated at 12 weeks, at which point statistically significant reductions in incontinence episodes, micturition frequency, and urgency were demonstrated. Your healthcare provider will likely assess the effectiveness of treatment after approximately 8 weeks and decide whether to continue based on your response. It is important to take the medication consistently every day to achieve the best possible outcome.
No, you must not crush, divide, or chew Mirabegron Avansor tablets. The tablets are specifically designed as prolonged-release (also called extended-release or modified-release) formulations. The matrix system inside the tablet controls the gradual release of mirabegron over an extended period as the tablet passes through your digestive system. Crushing or breaking the tablet would destroy this controlled-release mechanism, potentially causing the entire 50 mg dose to be released at once rather than gradually. This could lead to higher peak blood levels, increased risk of side effects (particularly cardiovascular effects such as increased heart rate and blood pressure), and potentially reduced duration of action. If you have difficulty swallowing tablets, speak with your doctor about alternative treatment options.
Mirabegron can be used in combination with the antimuscarinic agent solifenacin (Vesicare). This combination has been formally evaluated in clinical trials (BESIDE and SYNERGY studies) and has been shown to provide additional symptom improvement for patients who have not achieved adequate control with either medication alone. The combination targets two complementary pathways: mirabegron promotes bladder relaxation via beta-3 receptors while solifenacin reduces involuntary contractions by blocking muscarinic receptors. However, any combination of bladder medications should only be used under medical supervision, as there may be an increased risk of urinary retention, particularly in patients with bladder outlet obstruction such as benign prostatic hyperplasia.
Yes, mirabegron is generally well-suited for elderly patients and no dose adjustment is required based on age. In fact, mirabegron may be particularly advantageous in the elderly population compared with antimuscarinic medications. Older adults are more susceptible to anticholinergic side effects, including cognitive impairment, confusion, and delirium, which can be caused by antimuscarinic OAB treatments. The Beers Criteria and other geriatric prescribing guidelines recommend caution with antimuscarinics in the elderly. Mirabegron, with its non-anticholinergic mechanism of action, does not carry these cognitive risks and has demonstrated similar efficacy and safety in patients aged 65 and older compared with younger adults in clinical trial analyses.
References
- European Medicines Agency (EMA). Betmiga (mirabegron) – Summary of Product Characteristics. Last updated 2024. Available at: ema.europa.eu
- U.S. Food and Drug Administration (FDA). Myrbetriq (mirabegron) Extended-Release Tablets – Prescribing Information. Revised 2024. Available at: accessdata.fda.gov
- Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European–Australian phase 3 trial. Eur Urol. 2013;63(2):283–295. doi:10.1016/j.eururo.2012.10.016 (SCORPIO study)
- Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–1395. doi:10.1016/j.juro.2012.10.017 (ARIES study)
- Yamaguchi O, Marui E, Kakizaki H, et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007;100(3):579–587.
- Drake MJ, Chapple C, Esen AA, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol. 2016;70(1):136–145. doi:10.1016/j.eururo.2016.02.030
- Herschorn S, Chapple CR, Abrams P, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). Eur Urol. 2017;72(4):544–556. doi:10.1016/j.eururo.2017.05.018
- European Association of Urology (EAU). EAU Guidelines on Urinary Incontinence in Adults. 2023 Edition. Available at: uroweb.org
- Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455–2463. (Amended 2019)
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023. Available at: who.int
Medical Editorial Team
Medical Review
Board-certified specialists in urology and clinical pharmacology with extensive clinical experience in lower urinary tract dysfunction and pharmacotherapy.
Editorial Standards
All content follows GRADE evidence framework. Based on systematic reviews, randomized controlled trials, and international guidelines (EMA, FDA, EAU, ICS).
Independence
No pharmaceutical company funding or sponsorship. All editorial decisions are made independently based on the best available evidence.
Updates
Content is reviewed and updated regularly to reflect the latest clinical evidence, guideline updates, and regulatory decisions.
For questions about our editorial process, contact us at our contact page or review our editorial standards.